Ken Griffin Stoke Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 74,056 shares of STOK stock, worth $1.96 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

74,056

Previous 103,244 28.27%

Holding current value

$1.96 Million

Previous $1.17 Million 48.59%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$11.48 - $24.73 $335,078 - $721,819	-29,188 Reduced 28.27%	74,056 $1.74 Million
Q2 2025 Aug 14, 2025	SELL	$5.9 - $11.84 $25,476 - $51,125	-4,318 Reduced 4.01%	103,244 $1.17 Million
Q1 2025 May 15, 2025	BUY	$6.65 - $12.74 $99,630 - $190,870	14,982 Added 16.18%	107,562 $715,000
Q4 2024 Feb 14, 2025	BUY	$10.8 - $13.92 $924,804 - $1.19 Million	85,630 Added 1232.09%	92,580 $1.02 Million
Q3 2024 Nov 14, 2024	BUY	$12.24 - $15.92 $85,068 - $110,644	6,950 New	6,950 $85,000

Q4 2023 Feb 14, 2024	SELL	$3.37 - $5.4 $204,029 - $326,932	-60,543 Reduced 79.54%	15,577 $81,000
Q3 2023 Nov 14, 2023	SELL	$3.78 - $11.99 $363,552 - $1.15 Million	-96,178 Reduced 55.82%	76,120 $299,000
Q2 2023 Aug 14, 2023	SELL	$7.93 - $13.82 $413,684 - $720,947	-52,167 Reduced 23.24%	172,298 $1.83 Million
Q1 2023 May 15, 2023	SELL	$7.65 - $10.38 $650,563 - $882,725	-85,041 Reduced 27.48%	224,465 $1.87 Million
Q4 2022 Feb 14, 2023	BUY	$7.07 - $15.69 $266,715 - $591,905	37,725 Added 13.88%	309,506 $2.86 Million
Q3 2022 Nov 14, 2022	BUY	$12.56 - $22.53 $1.84 Million - $3.3 Million	146,544 Added 117.01%	271,781 $3.49 Million
Q2 2022 Aug 15, 2022	SELL	$10.36 - $23.93 $34,136 - $78,849	-3,295 Reduced 2.56%	125,237 $1.65 Million
Q1 2022 May 16, 2022	BUY	$17.19 - $26.1 $2.06 Million - $3.13 Million	120,110 Added 1426.15%	128,532 $2.71 Million
Q4 2021 Feb 14, 2022	SELL	$18.11 - $30.72 $379,313 - $643,430	-20,945 Reduced 71.32%	8,422 $202,000
Q3 2021 Nov 15, 2021	SELL	$23.65 - $34.44 $703,942 - $1.03 Million	-29,765 Reduced 50.34%	29,367 $747,000
Q2 2021 Aug 16, 2021	BUY	$30.53 - $41.09 $818,265 - $1.1 Million	26,802 Added 82.9%	59,132 $1.99 Million
Q1 2021 May 17, 2021	BUY	$36.08 - $69.81 $1.17 Million - $2.26 Million	32,330 New	32,330 $1.26 Million
Q2 2020 Aug 14, 2020	SELL	$20.26 - $29.73 $382,204 - $560,856	-18,865 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$16.8 - $34.15 $141,120 - $286,860	8,400 Added 80.27%	18,865 $432,000
Q4 2019 Feb 14, 2020	SELL	$20.01 - $30.79 $1.79 Million - $2.75 Million	-89,353 Reduced 89.52%	10,465 $296,000
Q2 2019 Aug 14, 2019	BUY	$25.53 - $29.17 $2.55 Million - $2.91 Million	99,818 New	99,818 $2.91 Million

Others Institutions Holding STOK

# of Institutions

160

Shares Held

60.2M

Call Options Held

563K

Put Options Held

101K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $1.05B
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account